New Recommendations Released for Treatment of IBS

Although irritable bowel syndrome (IBS) is the most common disease diagnosed by gastroenterologists, it’s also one of the most misunderstood. That’s why updated guidelines addressing the management of the condition are being released by the American College of Gastroenterology.

Through a comprehensive review of the latest medical research and expert consensus, the updated guidelines provide clinicians with a comprehensive and practical set of recommendations for the diagnosis and treatment of IBS.

“The last time the American College of Gastroenterology published guidelines for the management of IBS was in 2002, and the College recognized that in the span of five to six years there has been a remarkable explosion in knowledge that’s become available that’s helped us to understand the cause and management of IBS,” says William Chey, M.D., professor of medicine and director of the Gastrointestinal Physiology Laboratory at the University of Michigan Health System.

Along with Philip Schoenfeld, M.D., also of the U-M Division of Gastroenterology, Chey has helped to develop the new evidence-based recommendations.

IBS is a chronic disorder of the lower intestine that causes cramping, abdominal pain, bloating, constipation and/or diarrhea that affects 10 to 15 percent of the U.S. population. The new recommendations show that “there really are things to do for these patients; it’s not a hopeless situation,” says Chey.

Some of the most significant evidence-based recommendations from the guideline include:

• Most patients with typical IBS symptoms and no alarm features such as bleeding, weight loss, or a family history of colon cancer, inflammatory bowel disease or celiac sprue, do not need extensive diagnostic testing before confidently diagnosing IBS.
• IBS patients with diarrhea or a mixture of diarrhea and constipation should be screened with blood tests for celiac disease, a condition in which one cannot tolerate the gluten protein found in wheat and other grains.
• When patients with IBS and diarrhea undergo colonoscopy, biopsies should be obtained to rule out a rare disease called microscopic colitis.
• The use of anti-depressants, tricyclic agents and selective serotonin reuptake inhibitors, can be helpful for some patients with IBS. “There is a stronger recommendation that tricyclic antidepressants, used in low doses before people go to sleep at night, are an effective medicine for irritable bowel syndrome,” says Schoenfeld, associate professor of internal medicine at the U-M Medical School. The agents in these antidepressants can reduce bloating and discomfort by altering brain-gut signaling about motility and distention. He adds that constipation, a side effect of tricyclic antidepressants, is actually beneficial to many people in this population.